Filing Flows › Aclaris Therapeutics (ACRS) › Q2 2026 › vs Q2 2025
Aclaris Therapeutics (ACRS) Q2 2026 vs Q2 2025 (year over year)
Aclaris Therapeutics's revenue fell $148K (-8%) from $1.8M in Q2 2025 to $1.6M in Q2 2026. The biggest changes: Contract research −$86K (-19%); Licensing −$62K (-5%).
Aclaris Therapeutics, Q2 2026: revenue $1.6M (-8% year over year), net loss $21.5M, operating cash flow −$19.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Licensing | $1.3M | $1.3M | −$62K | -5% |
| Contract research | $356K | $442K | −$86K | -19% |
| Revenue | $1.6M | $1.8M | −$148K | -8% |
| Other income, net | $2.7M | $3.0M | −$246K | -8% |
| Net loss | $21.5M | $15.4M | $6.1M | +39% |
| Costs & expenses | $25.9M | $20.2M | $5.7M | +28% |
| Operating costs | $25.9M | $20.2M | $5.7M | +28% |
| Cost of revenue | $218K | $515K | −$297K | -58% |
| Research & development | $18.1M | $11.4M | $6.6M | +58% |
| General & admin | $6.0M | $5.4M | $662K | +12% |
| Other operating costs | $1.5M | $2.8M | −$1.3M | -46% |
| Operating cash sources | $22.6M | $13.2M | $9.5M | +72% |
| Depreciation & amortization | $107K | $114K | −$7K | -6% |
| Share-based compensation | $2.7M | $3.1M | −$391K | -13% |
| Cash used in operations | $19.8M | $10.0M | $9.9M | +99% |
| Net loss absorbed | $21.5M | $15.4M | $6.1M | +39% |
| Working capital & other | $1.1M | −$2.3M | $3.4M | — |
Questions
How much did Aclaris Therapeutics's revenue grow year over year in Q2 2026?
Aclaris Therapeutics's revenue fell $148K (-8%) from $1.8M in Q2 2025 to $1.6M in Q2 2026.
What drove Aclaris Therapeutics's revenue change in Q2 2026?
Contract research −$86K (-19%); Licensing −$62K (-5%).